Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F
Compose a Response to This Article
Other responses
No responses have been published for this article.